Autopsy and Case Reports
Autopsy and Case Reports
Clinical Case Report

Neuroendocrine breast carcinoma

Laura Pratas Guerra; Joana Simões; Diogo Carvalho Sá; José Polónia; António Araújo

Downloads: 0
Views: 268


Neuroendocrine breast cancer (NEBC) is a rare and heterogeneous entity. It most commonly presents a luminal phenotype and a worse prognosis. When diagnosed in an advanced stage, metastasis from another neuroendocrine tumor should be excluded.This case features a premenopausal woman with an oligometastatic breast large cell neuroendocrine carcinoma, estrogen receptor (ER) positive, and human epidermal growth factor receptor 2 (HER2) negative. Since the patient was very symptomatic at the presentation of the disease, chemotherapy was started. Complete radiological response of the metastatic disease was achieved, and the patient was then submitted to radical breast surgery and bilateral oophorectomy. She subsequently underwent radiation therapy. Since then and to date, she has been under endocrine therapy (ET) and a CDK4/6 inhibitor (CDK4/6i), with no evidence of malignant disease. Evidence to guide the choice of treatment for these tumors is currently scarce. In cases with oligometastatic disease, radical treatment should be considered. Given that this entity is rare, its reporting should be encouraged.


Carcinoma, Neuroendocrine, Breast Cancer, Pathology


1 Graca S, Esteves J, Costa S, Vale S, Maciel J. Neuroendocrine breast cancer. Case Rep. 2012;2012:bcr1220115343.

2 Cheymol C, Abramovici O, Do Cao C, et al. Tumeurs neuroendocrines primitives du sein: mythe ou réalité? Une revue de la littérature. Bull Cancer. 2018;105(4):431-9. PMid:29567279.

3 Muller K, Jorns M, Tozbikian G. What’s new in breast pathology 2022: WHO 5th edition and biomarker updates. J Pathol Transl Med. 2022;56(3):170-1.

4 Tsang JY, Tse GM. Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification. Mod Pathol. 2021;34(6):1062-73. PMid:33531618.

5 Ma ST, Wang D, Liu Y, et al. Prognostic factors of primary neuroendocrine breast cancer: a population‐based study. Cancer Med. 2022;11(13):2533-40. PMid:35499193.

6 Shanks A, Choi J, Karur V. Dramatic response to cyclin D dependent kinase 4/6 inhibitor in refractory poorly differentiated neuroendocrine carcinoma of the breast. Proc Bayl Univ Med Cent. 2018;31(3):352-4.

7 Alkaied H, Harris K, Azab B, Dai Q. Primary neuroendocrine breast cancer, how much do we know so far? Med Oncol. 2012;29(4):2613-8. PMid:22467078.

8 Tsang JY, Tse GM. Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification. Mod Pathol. 2021;34(6):1062-73. PMid:33531618.

9 Rosa M, Sheikh U, Nasir A. Breast carcinomas with neuroendocrine features (neuroendocrine carcinomas of the breast). In: Nair A, Coppola D, editors. Neuroendocrine tumors: review of pathology, molecular and therapeutic advances. New York: Spinger; 2016. p. 179-201.

10 Gallo M, Campione S, Di Vito V, et al. Primary neuroendocrine neoplasms of the breast: still open issues. Front Endocrinol (Lausanne). 2021;11:610230. PMid:33584543.

11 Trevisi E, La Salvia A, Daniele L, et al. Neuroendocrine breast carcinoma: a rare but challenging entity. Med Oncol. 2020;37(8):70. PMid:32712767.

12 Inno A, Bogina G, Turazza M, et al. Neuroendocrine carcinoma of the breast: current evidence and future perspectives. Oncologist. 2016;21(1):28-32. PMid:26659223.

Submitted date:

Accepted date:

Publication date:

65fc12b4a953952b801cf695 autopsy Articles
Links & Downloads

Autops Case Rep

Share this page
Page Sections